Xconomy’s Digital Events →
Venture capitalists are not evil. That is the message that Bill Bryant, the prominent Seattle venture capitalist and venture partner at Draper Fisher Jurvetson, had for Seattle technology entrepreneurs earlier this... Read more »
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.